Key points: The lower doses of semaglutide can wear off after 4-5 days It can take up to 4-5 weeks for the medication to reach a steady state where its levels are consistent in the blood Weight loss may be steady at the beginning but become more consistent as you increase your dose Practical strategies to enhance semaglutide results in the UK Nutrition tips Prioritise protein at every meal (aim for 1.6-2g per kg of body weight daily) Stay well-hydrated (2-3 litres daily) to manage common side effects Consider splitting meals into smaller, more frequent portions if you feel full quickly Limit ultra-processed foods which may trigger cravings despite medication Physical activity guidance Include resistance training 2-3 times weekly to preserve muscle mass Aim to move a little bit each day, even a 5 minute walk as developing the habit of movement is more important than rigid targets when first starting Try exercise snacking, like calf raises when the kettle is boiling, or push-ups when youve been to the toilet Planning for the future Develop strategies for maintaining weight loss after treatment Learn how to safely transition off semaglutide when the time comes Frequently asked questions How do I access semaglutide on the NHS in the UK
Decreases Inflammatory Response : Excess weight can contribute to a systemic inflammatory state in the body, exacerbating the inflammation caused by uric acid crystals in the joints
GLP-1 receptor agonists, which mimic the hormone Glucagon-Like Peptide-1, are transforming treatment for diabetes and obesity
Additionally, we stated in the CY 2026 OPPS/ASC proposed rule that we believe that the pass-through payment category C1765 may also appropriately describe the Axoguard HA+ Nerve Protector TM because the device, as described by the applicant, is designed to be placed on and around neural structures to be a protective interface between a nerve and the surrounding tissue, to minimize the potential for soft tissue attachments, and to ensure the nerve's ability to glide through tissue structures during anatomic movement, and therefore may be appropriately described as an adhesion barrier consistent with devices described by C1765
